PredicineRNA™ identifies RNA-based gene fusions and splicing variants, enabling detection of known and novel gene fusions. Gene fusions and splicing variants have been recognized as tumor drivers, providing new targets for personalized therapy.
PredicineRNA™ is a laboratory developed test. It is for research use only.
Our pilot program is available to select biopharma and academic partners to accelerate biomarker discoveries and biomarker-driven clinical studies. To initiate a study, contact us via the form below.